Literature DB >> 19175605

Prostaglandin E(2) couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines.

I Dey1, M A Giembycz, K Chadee.   

Abstract

BACKGROUND AND
PURPOSE: Prostaglandin (PG) E(2) and interleukin (IL)-8 are simultaneously increased during the inflammation that characterizes numerous pathologies such as inflammatory bowel disease. IL-8 is a potent neutrophil chemo-attractant and activator, and can initiate and/or exacerbate tissue injury. PGE(2) signals principally through prostanoid receptors of the EP(2) and/or EP(4) subtypes to promote cAMP-dependent cellular functions. The aim of this study was to identify the role of the EP(2) and EP(4) receptor subtype(s) on two human colonic epithelial cell lines (Caco-2 and T84), in regulating PGE(2)-induced IL-8 production. EXPERIMENTAL APPROACH: To identify the causative receptor, we knocked-down and over-expressed EP(2) and EP(4) receptor subtypes in colonic epithelial cells and studied the effect of several selective EP(2)/EP(4) receptor agonists and antagonists. The inductions of IL-8 and EP receptor mRNA and protein expression were determined by real-time PCR and western blot analysis. The affinity of PGE(2) and Bmax values for the EP(2) and EP(4) receptor on colonic epithelial cells were determined by radioligand-binding assays with [(3)H]PGE(2). KEY
RESULTS: PGE(2) had the highest affinity for the EP(4) receptor subtype and promoted a robust stimulation of cAMP-dependent IL-8 synthesis. This effect was mimicked by a selective EP(4) receptor agonist, ONO-AE1-329, and abolished by silencing the EP(4) receptor gene by using siRNA techniques, a selective EP(4) receptor antagonist (ONO-AE3-208) and a selective inhibitor (Rp-cAMP) of cAMP-dependent protein kinase. CONCLUSIONS AND IMPLICATIONS: These findings suggest that initiation and progression of colonic inflammation induced by IL-8 could be mediated, at least in part, by PGE(2) acting via the EP(4) receptor subtype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19175605      PMCID: PMC2697677          DOI: 10.1111/j.1476-5381.2008.00056.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

Review 1.  Prostanoid receptors: subtypes and signaling.

Authors:  R M Breyer; C K Bagdassarian; S A Myers; M D Breyer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

2.  The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.

Authors:  M Abramovitz; M Adam; Y Boie; M Carrière; D Denis; C Godbout; S Lamontagne; C Rochette; N Sawyer; N M Tremblay; M Belley; M Gallant; C Dufresne; Y Gareau; R Ruel; H Juteau; M Labelle; N Ouimet; K M Metters
Journal:  Biochim Biophys Acta       Date:  2000-01-17

Review 3.  RNA interference--2001.

Authors:  P A Sharp
Journal:  Genes Dev       Date:  2001-03-01       Impact factor: 11.361

4.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

5.  Prostaglandin E(2) stimulates rat and human colonic mucin exocytosis via the EP(4) receptor.

Authors:  A Belley; K Chadee
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

6.  Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis.

Authors:  Michihiro Mutoh; Kouji Watanabe; Tomohiro Kitamura; Yutaka Shoji; Mami Takahashi; Toshihiko Kawamori; Kousuke Tani; Michiyoshi Kobayashi; Takayuki Maruyama; Kaoru Kobayashi; Shuichi Ohuchida; Yukihiko Sugimoto; Shuh Narumiya; Takashi Sugimura; Keiji Wakabayashi
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

7.  Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.

Authors:  T L Davis; N A Sharif
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  Prostanoid receptors in intestinal epithelium: selective expression, function, and change with inflammation.

Authors:  V Takafuji; R Cosme; D Lublin; K Lynch; J K Roche
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2000-10       Impact factor: 4.006

9.  The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut.

Authors:  Kenji Kabashima; Tomomi Saji; Takahiko Murata; Miyako Nagamachi; Toshiyuki Matsuoka; Eri Segi; Kazuhito Tsuboi; Yukihiko Sugimoto; Takuya Kobayashi; Yoshiki Miyachi; Atsushi Ichikawa; Shuh Narumiya
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

10.  Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor.

Authors:  Kiyoshi Takayama; Guillermo García-Cardena; Galina K Sukhova; Jason Comander; Michael A Gimbrone; Peter Libby
Journal:  J Biol Chem       Date:  2002-09-04       Impact factor: 5.157

View more
  12 in total

1.  NF-κB-dependent IL-8 induction by prostaglandin E(2) receptors EP(1) and EP(4).

Authors:  F Neuschäfer-Rube; A Pathe-Neuschäfer-Rube; S Hippenstiel; M Kracht; G P Püschel
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

2.  Prostaglandin E2 produced by Entamoeba histolytica signals via EP4 receptor and alters claudin-4 to increase ion permeability of tight junctions.

Authors:  Manigandan Lejeune; France Moreau; Kris Chadee
Journal:  Am J Pathol       Date:  2011-05-31       Impact factor: 4.307

3.  Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats.

Authors:  D Peter; R Göggel; F Colbatzky; P Nickolaus
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

4.  NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations.

Authors:  Leanne Mortimer; France Moreau; Justin A MacDonald; Kris Chadee
Journal:  Nat Immunol       Date:  2016-08-22       Impact factor: 25.606

5.  Maternal and neonatal dietary intake of balanced n-6/n-3 fatty acids modulates experimental colitis in young adult rats.

Authors:  K Vijay Kumar Reddy; K Akhilender Naidu
Journal:  Eur J Nutr       Date:  2015-08-06       Impact factor: 5.614

6.  Loss of EP2 receptor subtype in colonic cells compromise epithelial barrier integrity by altering claudin-4.

Authors:  Manigandan Lejeune; France Moreau; Kris Chadee
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

7.  EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease.

Authors:  Karina Thieme; Syamantak Majumder; Angela S Brijmohan; Sri N Batchu; Bridgit B Bowskill; Tamadher A Alghamdi; Suzanne L Advani; M Golam Kabir; Youan Liu; Andrew Advani
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

8.  Lymphocytic colitis is associated with increased pro-inflammatory cytokine profile and up regulation of prostaglandin receptor EP4.

Authors:  Indranil Dey; Paul L Beck; Kris Chadee
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

Review 9.  E-type prostanoid receptor 4 (EP4) in disease and therapy.

Authors:  Viktoria Konya; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Journal:  Pharmacol Ther       Date:  2013-03-21       Impact factor: 12.310

10.  Prostaglandin E2 Induces IL-6 and IL-8 Production by the EP Receptors/Akt/NF-κB Pathways in Nasal Polyp-Derived Fibroblasts.

Authors:  Jung-Sun Cho; In-Hye Han; Hye Rim Lee; Heung-Man Lee
Journal:  Allergy Asthma Immunol Res       Date:  2014-06-04       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.